The company picked Dominic Klyve to serve as CSO, while John Cronin takes up the interim CTO role.
Seattle-based Know Labs develops non-invasive diagnostic technology, including a wearable continuous glucose monitor (CGM). The company unveiled KnowU, its wearable CGM set for FDA submission, earlier this year. KnowU’s sensor uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The technology integrates into wearable, mobile or bench-top form factors.
Know Labs said it tasked both new executives with furthering the development of its technology and building relationships with potential strategic partners.
Klyve, a long-time consultant and previous Know Labs employee, previously served as lead data scientist at the company. His new responsibilities as CSO include leading R&D to build the company’s first non-invasive glucose monitor.
Cronin joins the day-to-day team as CTO, as an already-serving member of the company’s board of directors. He previously served as a strategic advisor and consultant to the company as well. His new interim role includes overseeing product development and technology strategy and protocol testing as well. Cronin, who began his career at IBM, is the current founder and CEO of ipCapital Group, a global advisory company for intellectual property strategy and monetization.
“John and Dominic bring extensive technology leadership and research experience to the Know Labs team,” said Ron Erickson, CEO. “In their new roles they provide intellectual leadership to both drive our technology development and real-world business acumen to assist in bringing our platform to market through strategic relationships with global leaders in the med tech, pharma and consumer marketplace.”
